Marktanalyse - Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
64 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) — Pipeline Review, H2 2016, provides an overview of the Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 2, 1, 4 and 1 respectively.

Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Granulomatosis with Polyangiitis (Wegener Polyangiitis) Overview 7

Therapeutics Development 8

Pipeline Products for Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Overview 8

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Therapeutics under Development by Companies 9

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Products under Development by Companies 14

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Companies Involved in Therapeutics Development 15

Bionovis SA 15

Bristol-Myers Squibb Company 16

ChemoCentryx Inc 17

Coherus BioSciences Inc 18

Genor BioPharma Co Ltd 19

GlaxoSmithKline Plc 20

Iltoo Pharma 21

Panacea Biotec Ltd 22

Sandoz International GmbH 23

The International Biotechnology Center (IBC) Generium 24

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

abatacept - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

aldesleukin - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

avacopan - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

belimumab - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

rituximab biosimilar - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

rituximab biosimilar - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

rituximab biosimilar - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

rituximab biosimilar - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

rituximab biosimilar - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

rituximab biosimilar - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

rituximab biosimilar - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Dormant Projects 60

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Discontinued Products 61

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Product Development Milestones 62

Featured News & Press Releases 62

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64





List of Tables

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Comparative Analysis by Unknown Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Bionovis SA, H2 2016 15

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Bristol-Myers Squibb Company, H2 2016 16

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by ChemoCentryx Inc, H2 2016 17

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Coherus BioSciences Inc, H2 2016 18

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Genor BioPharma Co Ltd, H2 2016 19

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by GlaxoSmithKline Plc, H2 2016 20

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Iltoo Pharma, H2 2016 21

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Panacea Biotec Ltd, H2 2016 22

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Sandoz International GmbH, H2 2016 23

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Dormant Projects, H2 2016 60

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Discontinued Products, H2 2016 61





List of Figures

Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus